Abstract
Based on impressive morbidity and mortality data using β blockers in heart failure, this therapy has now become part of the standard of care for patients with New York Heart Association II/III symptoms. The question remains whether there are clinically relevant differences between the β blockers that have shown beneficial effects. This review summarizes the major mortality trials, and examines the smaller comparative trials of second and third generation β blockers.
| Original language | English |
|---|---|
| Pages (from-to) | 153-157 |
| Number of pages | 5 |
| Journal | Congestive Heart Failure |
| Volume | 6 |
| Issue number | 3 |
| State | Published - 2000 |